AU2009217237A1 - Therapeutic peptides - Google Patents
Therapeutic peptides Download PDFInfo
- Publication number
- AU2009217237A1 AU2009217237A1 AU2009217237A AU2009217237A AU2009217237A1 AU 2009217237 A1 AU2009217237 A1 AU 2009217237A1 AU 2009217237 A AU2009217237 A AU 2009217237A AU 2009217237 A AU2009217237 A AU 2009217237A AU 2009217237 A1 AU2009217237 A1 AU 2009217237A1
- Authority
- AU
- Australia
- Prior art keywords
- dendrimer
- amino acid
- polypeptide
- seq
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2009217237A AU2009217237A1 (en) | 2008-02-22 | 2009-02-23 | Therapeutic peptides |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2008900848A AU2008900848A0 (en) | 2008-02-22 | Therapeutic peptides | |
| AU2008900848 | 2008-02-22 | ||
| AU2009217237A AU2009217237A1 (en) | 2008-02-22 | 2009-02-23 | Therapeutic peptides |
| PCT/AU2009/000201 WO2009103127A1 (en) | 2008-02-22 | 2009-02-23 | Therapeutic peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2009217237A1 true AU2009217237A1 (en) | 2009-08-27 |
Family
ID=40985007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2009217237A Abandoned AU2009217237A1 (en) | 2008-02-22 | 2009-02-23 | Therapeutic peptides |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110105408A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2254901A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2011512364A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2009217237A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2009103127A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010215086A1 (en) * | 2009-02-23 | 2011-09-08 | Inter-K Pty Limited | Inhibition of multiple cell activation pathways |
| EP3228714B1 (en) | 2010-12-14 | 2019-03-27 | Stichting Katholieke Universiteit | Chemiluminescence-based haemostasis assay |
| CN104271590B (zh) * | 2012-01-24 | 2018-06-05 | Inter-K私人有限公司 | 用于癌治疗的肽剂 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4177263A (en) * | 1972-02-28 | 1979-12-04 | Research Corporation | Anti-animal tumor method |
| US5962643A (en) * | 1991-07-11 | 1999-10-05 | The Regents Of The University Of California | Integrin β subunit and uses thereof |
| US6514745B1 (en) * | 1993-07-19 | 2003-02-04 | The Regents Of The University Of California | Oncoprotein protein kinase |
| US5807746A (en) * | 1994-06-13 | 1998-09-15 | Vanderbilt University | Method for importing biologically active molecules into cells |
| US6495518B1 (en) * | 1994-06-13 | 2002-12-17 | Vanderbilt University | Method for importing biologically active molecules into cells |
| US5877282A (en) * | 1996-09-20 | 1999-03-02 | Bristol-Myers Squibb Company | Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof |
| US6495514B1 (en) * | 1998-01-21 | 2002-12-17 | Mercer University | Method for reducing inflammation and inducing an analgesic effect and compounds thereof |
| US6248558B1 (en) * | 1998-03-31 | 2001-06-19 | Vanderbilt University | Sequence and method for genetic engineering of proteins with cell membrane translocating activity |
| JP4439120B2 (ja) * | 1998-10-16 | 2010-03-24 | 大塚製薬株式会社 | 新生血管特異的ペプチド |
| ATE385503T1 (de) * | 1999-06-28 | 2008-02-15 | Inter K Pty Ltd | Verfahren zur modulierung von integrin- vermittelter zellaktivitaet und hierfuer geeignete reagenzien |
| US6312956B1 (en) * | 1999-10-01 | 2001-11-06 | Vanderbilt University | Nuclear targeted peptide nucleic acid oligomer |
| US6471968B1 (en) * | 2000-05-12 | 2002-10-29 | Regents Of The University Of Michigan | Multifunctional nanodevice platform |
| AUPR230500A0 (en) * | 2000-12-22 | 2001-01-25 | University Of Newcastle Research Associates Limited, The | A method of modulating map kinase mediated cellular activity and agents useful in same |
| EP1684795A4 (en) * | 2003-10-17 | 2009-07-29 | Inter K Pty Ltd | METHODS AND AGENTS FOR THE TREATMENT OF CANCER |
| US20060257359A1 (en) * | 2005-02-28 | 2006-11-16 | Cedric Francois | Modifying macrophage phenotype for treatment of disease |
| US20060204443A1 (en) * | 2005-03-11 | 2006-09-14 | The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services | Methods for tumor treatment using dendrimer conjugates |
-
2009
- 2009-02-23 US US12/735,869 patent/US20110105408A1/en not_active Abandoned
- 2009-02-23 WO PCT/AU2009/000201 patent/WO2009103127A1/en not_active Ceased
- 2009-02-23 EP EP09713470A patent/EP2254901A4/en active Pending
- 2009-02-23 JP JP2010547006A patent/JP2011512364A/ja active Pending
- 2009-02-23 AU AU2009217237A patent/AU2009217237A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011512364A (ja) | 2011-04-21 |
| EP2254901A1 (en) | 2010-12-01 |
| WO2009103127A1 (en) | 2009-08-27 |
| EP2254901A4 (en) | 2012-02-22 |
| US20110105408A1 (en) | 2011-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2992008B1 (en) | Therapeutic peptides | |
| CN106456697B (zh) | 具有纤维化抑制活性的肽和含有其的组合物 | |
| US9340579B2 (en) | DPP-4 inhibitor | |
| AU2008273813B2 (en) | Bioactive peptides and method of using same | |
| CN102470156A (zh) | 选择性作用于αvβ3整合素并缀合人血清白蛋白(HSA)变体的多肽及其药学用途 | |
| IL223678A (en) | Immunosuppressive Modulation Compounds | |
| US9757473B2 (en) | Cell-penetrating peptide and conjugate comprising same | |
| US20120277161A1 (en) | Inhibition of multiple cell activation pathways | |
| WO2018166119A1 (zh) | 一种多肽或其衍生物及其在制备治疗肿瘤的药物中的应用 | |
| US11033609B2 (en) | Cyclic acetylcholinesterase C-terminal peptide in the treatment or prevention of cancer or metastasis | |
| TW201838647A (zh) | 對胰島素受體有降低親和性之胰島素類似物之接合物及其用途 | |
| US9765113B2 (en) | Methods and agents for the treatment of cancer | |
| US20110105408A1 (en) | Therapeutic peptides | |
| WO2010086867A2 (en) | Peptides, pharmaceutical compositions comprising same and uses thereof | |
| EP2398484A1 (en) | Inhibition of multiple cell activation pathways | |
| CA2989353A1 (en) | B1sp fusion protein for the treatment of cancer | |
| WO2016097753A1 (en) | Cyclic acetylcholinesterase c-terminal peptide in the treatment or prevention of cancer or metastasis | |
| WO2021098996A1 (en) | Oligopeptides that inhibit angiogenesis and vascular function | |
| CN113842466B (zh) | 一种分子包裹萘莫司他及其在治疗三阴性乳腺癌中的应用 | |
| CN103833841A (zh) | Exendin-4类似物二聚体及其制备方法和应用 | |
| HK1227414B (zh) | Dpp-4抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |